Heidegger Mateos‐Toledo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Heidegger Mateos‐Toledo has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Arturo Cortes-Telles
Clínica de Enfermedades Respiratorias. Hospital Regional de Alta Especialidad de la Península de Yucatán IMSS-Bienestar, Yucatán
1 shared publication - Gerald Stanley Zavorsky
Department of Physiology and Membrane Biology University of California at Davis Davis California USA
1 shared publication - Jordan A. Guenette
Centre for Heart Lung Innovation, Providence Research The University of British Columbia (UBC) and St. Paul's Hospital Vancouver British Columbia Canada
1 shared publication - Jorge Rojas-Serrano
Interstitial Lung disease and Rheumatology Unit, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico
1 shared publication Luis Alberto Solís‐Díaz
Clínica de Enfermedades Respiratorias, Hospital Regional de Alta Especialidad de la Península de Yucatán, IMSS‐Bienestar Mérida Mexico
1 shared publication- Mayra Mejía
Interstitial Lung Disease and Rheumatology Unit, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico City 14080, Mexico
1 shared publication
Latest Publications
- Open Access
- 24 October 2024
- Published by Wiley in Experimental Physiology
- Vol. 109 (12) , 2147-2157
Mexican Hispanics show significant improvement in lung function approximately 1 year after having severe COVID‐19
The long‐term effects of COVID‐19 on lung function are not understood, especially for periods extending beyond 1 year after infection. This observational, longitudinal study investigated lung function in Mexican Hispanics who experienced severe COVID‐19, focusing on how the length of recovery affects lung function improvements. At a specialized COVID‐19 follow‐up clinic in Yucatan, Mexico, lung function and symptoms were assessed in patients who had recovered from severe COVID‐19. We used z‐scores, and Wilcoxon's signed rank test to analyse changes in lung function over time. Lung function was measured twice in 82 patients: the first and second measurements were taken a median of 94 and 362 days after COVID‐19 diagnosis, respectively. Initially, 61% of patients exhibited at least one of several pulmonary function abnormalities (lower limit of normal = –1.645), which decreased to 22% of patients by 390 days post‐recovery. Considering day‐to‐day variability in lung function, 68% of patients showed improvement by the final visit, while 30% had unchanged lung function from the initial assessment. Computed tomography (CT) scans revealed ground‐glass opacities in 33% of patients. One year after infection, diffusing capacity of the lungs for carbon monoxide z‐scores accounted for 30% of the variation in CT fibrosis scores. There was no significant correlation between the length of recovery and improvement in lung function based on z‐scores. In conclusion, 22% of patients who recovered from severe COVID‐19 continued to show at least one lung function abnormality 1 year after recovery, indicating a prolonged impact of COVID‐19 on lung health.
- 24 October 2024
- Published by Wiley in Experimental Physiology
- Vol. 109 (12) , 2147-2157
Open AccessMexican Hispanics show significant improvement in lung function approximately 1 year after having severe COVID‐19
The long‐term effects of COVID‐19 on lung function are not understood, especially for periods extending beyond 1 year after infection. This observational, longitudinal study investigated lung function in Mexican Hispanics who experienced severe COVID‐19, focusing on how the length of recovery affects lung function improvements. At a specialized COVID‐19 follow‐up clinic in Yucatan, Mexico, lung function and symptoms were assessed in patients who had recovered from severe COVID‐19. We used z‐scores, and Wilcoxon's signed rank test to analyse changes in lung function over time. Lung function was measured twice in 82 patients: the first and second measurements were taken a median of 94 and 362 days after COVID‐19 diagnosis, respectively. Initially, 61% of patients exhibited at least one of several pulmonary function abnormalities (lower limit of normal = –1.645), which decreased to 22% of patients by 390 days post‐recovery. Considering day‐to‐day variability in lung function, 68% of patients showed improvement by the final visit, while 30% had unchanged lung function from the initial assessment. Computed tomography (CT) scans revealed ground‐glass opacities in 33% of patients. One year after infection, diffusing capacity of the lungs for carbon monoxide z‐scores accounted for 30% of the variation in CT fibrosis scores. There was no significant correlation between the length of recovery and improvement in lung function based on z‐scores. In conclusion, 22% of patients who recovered from severe COVID‐19 continued to show at least one lung function abnormality 1 year after recovery, indicating a prolonged impact of COVID‐19 on lung health.
- Open Access
- 6 June 2014
- Published by Wiley in Arthritis & Rheumatology
- Vol. 66 (9) , 2641-2642
Methotrexate and Lung Disease in Rheumatoid Arthritis: Comment on the Article by Conway et al
- 6 June 2014
- Published by Wiley in Arthritis & Rheumatology
- Vol. 66 (9) , 2641-2642
Open AccessMethotrexate and Lung Disease in Rheumatoid Arthritis: Comment on the Article by Conway et al